Sarah Lochren, PA
Physician Assistant · Pascagoula, MSNPI 1497007009
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,217 of the $3,817 with a category attached, or 84.3%. It is spread thinly across 40 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,250, 8.3 times the $270 reported in 2021.
Across 155 payments — averaging $24.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$819
- Johnson & Johnson$423
- Novartis$316
- Merck$255
- Incyte Corporation$194
- Bristol Myers Squibb$139
- plus $2K from 34 others
What the payments were for
- Speaking & faculty fees$3509%
- Food & beverage$3,21784%
- Education$2507%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 23 | $819 |
| Johnson & Johnson | 16 | $423 |
| Novartis | 15 | $316 |
| Merck | 12 | $255 |
| Incyte Corporation | 9 | $194 |
| Bristol Myers Squibb | 5 | $139 |
| Genentech USA, Inc. | 6 | $114 |
| Pharmaessentia USA Corporation | 4 | $114 |
| AbbVie | 4 | $111 |
| Astellas Pharma US Inc | 4 | $100 |
| Exelixis Inc. | 4 | $91 |
| Beone Medicines USA, Inc. | 4 | $90 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| Ipsen Biopharmaceuticals, Inc | 4 | $75 |
| Daiichi Sankyo Inc. | 3 | $74 |
| E.r. Squibb & Sons, L.L.C. | 4 | $71 |
| Legend Biotech USA Inc. | 3 | $68 |
| Adaptive Biotechnologies Corporation | 2 | $55 |
| Eisai Inc. | 3 | $54 |
| Bayer | 2 | $44 |
| Rigel Pharmaceuticals, Inc. | 2 | $43 |
| GSK | 2 | $42 |
| Array Biopharma Inc | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| Lilly USA, LLC | 2 | $38 |
| Boehringer Ingelheim | 2 | $34 |
| Puma Biotechnology, Inc. | 2 | $30 |
| Servier Pharmaceuticals LLC | 1 | $28 |
| Stemline Therapeutics Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Taiho Oncology, Inc. | 1 | $22 |
| Beigene USA, Inc. | 1 | $20 |
| Kerecis Limited | 1 | $19 |
| Pfizer | 1 | $19 |
| Genmab U.S., Inc. | 1 | $19 |
| Agios Pharmaceuticals, Inc. | 1 | $19 |
| Caris MPI, Inc. | 1 | $18 |
| Seagen Inc. | 1 | $16 |
| Medtronic | 1 | $14 |
| Myriad Genetic Laboratories, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,817 in reported general payments places this provider in the 80th percentile of 278 physician assistant providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 11 | $200,210 |
| EliquisApixaban | 39 | $34,328 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 14 | $24,255 |
| XareltoRivaroxaban | 22 | $20,463 |
| Hydroxyurea | 37 | $969 |
| Letrozole | 52 | $746 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 14 | $670 |
| Anastrozole | 46 | $549 |
| Tamoxifen Citrate | 23 | $546 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 31 | $505 |
| Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12) | 15 | $276 |
| Oxycodone Hcl | 13 | $173 |
| Megestrol Acetate | 12 | $158 |
| Tramadol Hcl | 18 | $130 |
| Pregabalin | 16 | $110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $139 | $200,21011 claims |
| PfizerEliquis | $19 | $34,32839 claims |
| Johnson & JohnsonXarelto | $423 | $20,46322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 278 physician assistant providers in Mississippi.
Other physician assistant in Pascagoula
- Lavinia DrambareanHattiesburg$382K
- Karmen ClarkOcean Springs$49K
- Kristen RichardsonFlowood$21K
- Connie KlotzbachOcean Springs$20K
- Nichole HornHattiesburg$19K
- Hannah SavelyTupelo$13K
- Barry FlippoSouthaven$13K
- Mary AdamsOcean Springs$13K
- Siera ShiyouJackson$12K
- Katie McDanielOxford$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.